| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/30/2006 | US20060068437 Meg-3 protein |
| 03/30/2006 | US20060068420 Regulation of Th2 cell activity by modulation of NFATp and NFAT4 activity |
| 03/30/2006 | US20060068389 Methods and compositions for inhibiting hiv replication |
| 03/30/2006 | US20060068379 Phage display of intact domains at high copy number |
| 03/30/2006 | US20060068032 Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of Angelica sinensis, and methods of preparation thereof |
| 03/30/2006 | US20060068027 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| 03/30/2006 | US20060067997 Phospholipid complexes of lexitropsins, their preparation and use in therapeutic formulations |
| 03/30/2006 | US20060067988 Pharmaceutical formulations designed to supplement the diet of anorexic patients |
| 03/30/2006 | US20060067986 Mixture of milk, protein such as casein and enzyme inhibiting peptide |
| 03/30/2006 | US20060067972 Devices for renal-based heart failure treatment |
| 03/30/2006 | US20060067951 Signal peptides, nucleic acid molecules and methods for treatment of caries |
| 03/30/2006 | US20060067949 Immunization with porphyromonas gingivalis protects against heart disease |
| 03/30/2006 | US20060067948 Viral vectors |
| 03/30/2006 | US20060067946 Method of treatment using ligand-immunogen conjugates |
| 03/30/2006 | US20060067944 Stable immunogenic product comprising antigenic heterocomplexes |
| 03/30/2006 | US20060067938 Methods for the treatment of osteoarthritis and compositions thereof |
| 03/30/2006 | US20060067937 Methods of diagnosing and treating complications of pregnancy |
| 03/30/2006 | US20060067934 DNA sequences encoding tumor necrosis factor receptors; recombinant expression vectors |
| 03/30/2006 | US20060067932 Antagonists specific for denatured collagen and methods of using same |
| 03/30/2006 | US20060067929 Administering a modified Clostridial toxin with a proteolytic domain; a translocation domain and an orphanin targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction. |
| 03/30/2006 | US20060067928 Contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [ alpha -L-iduronic acid (I) or beta -D-glucuronic acid] linked 1, 4 to alpha -D-hexosamine with a modified heparinase III in vitro |
| 03/30/2006 | US20060067927 Methods and compositions related to the modulation of intercellular junctions |
| 03/30/2006 | US20060067926 Novel serine threonine kinase member, h2520-59 |
| 03/30/2006 | US20060067925 Method and composition for inhibiting reperfusion injury in the brain |
| 03/30/2006 | US20060067917 Insulin delivery system |
| 03/30/2006 | US20060067913 HCV therapy |
| 03/30/2006 | US20060067912 Methods for the induction of professional and cytokine-producing regulatory T cells |
| 03/30/2006 | US20060067911 Metered medication dose |
| 03/30/2006 | US20060067909 Peptide-modified polyurethane compositions and associated methods |
| 03/30/2006 | US20060067891 Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin |
| 03/30/2006 | DE19911771B4 LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung LHRH antagonist, process for its preparation and its use |
| 03/30/2006 | DE102004044556A1 Use of kinase inhibitors (e.g. serine/threonine kinase inhibitors) for treating viral infections caused by human cytomegalo virus |
| 03/30/2006 | DE102004043750A1 Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität Formulations of the peptide p277 or its variants with improved stability |
| 03/30/2006 | CA2797769A1 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions |
| 03/30/2006 | CA2619256A1 Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover |
| 03/30/2006 | CA2581423A1 Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| 03/30/2006 | CA2581336A1 Methods of diagnosing and treating complications of pregnancy |
| 03/30/2006 | CA2581330A1 Methods and compositions relating to mannuronic acid specific binding peptides |
| 03/30/2006 | CA2581319A1 Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
| 03/30/2006 | CA2581093A1 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use |
| 03/30/2006 | CA2580881A1 Use of microproteins as tryptase inhibitors |
| 03/30/2006 | CA2580679A1 Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| 03/30/2006 | CA2580501A1 G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| 03/30/2006 | CA2580494A1 Biomarkers for breast cancer |
| 03/30/2006 | CA2580281A1 Treatment of bone disorders with skeletal anabolic drugs |
| 03/30/2006 | CA2580224A1 Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
| 03/30/2006 | CA2579630A1 Pik4ca as modifier of the rac pathway and methods of use |
| 03/30/2006 | CA2579166A1 Use of il-17f for the treatment and/or prevention of neurologic diseases |
| 03/30/2006 | CA2578428A1 Ring-closing metathesis process in supercritical fluid |
| 03/30/2006 | CA2577831A1 Process for preparing macrocyclic hcv protease inhibitors |
| 03/30/2006 | CA2577632A1 Intestinal epithelial glucose sensor |
| 03/29/2006 | EP1640382A1 Anti-angiogenic peptides |
| 03/29/2006 | EP1640381A2 Neurotrophic growth factor |
| 03/29/2006 | EP1640024A2 Cell-coated support |
| 03/29/2006 | EP1640020A1 Cardioprotective agent |
| 03/29/2006 | EP1640019A1 Sustained-release fine granular preparation of human growth hormone and process for producing the same |
| 03/29/2006 | EP1640018A1 Combinational therapy for treating cancer |
| 03/29/2006 | EP1640017A1 Remedies for diseases with hypermyotonia |
| 03/29/2006 | EP1640003A2 Compositions comprising a Cyclooxygenase-2 Inhibitor and a Leukotriene B4 receptor antagonist |
| 03/29/2006 | EP1639903A1 Composition and foods for lowering glycemic index |
| 03/29/2006 | EP1639108A2 Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| 03/29/2006 | EP1639101A2 Odor control compositions and methods |
| 03/29/2006 | EP1639097A2 Methods and compositions for modulating stem cell growth and differentiation |
| 03/29/2006 | EP1639086A2 Rna interferases and methods of use thereof |
| 03/29/2006 | EP1639085A2 Modified human acid sphingomyelinase having increased activity, and methods for making the same |
| 03/29/2006 | EP1639080A2 A library of phylogenetically related sequences |
| 03/29/2006 | EP1639029A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/29/2006 | EP1639008A1 Ubiquitinated tnf receptor 2 and its uses |
| 03/29/2006 | EP1639007A2 Vegf traps and therapeutic uses thereof |
| 03/29/2006 | EP1639006A1 Use of a vegf receptor gene or gene product |
| 03/29/2006 | EP1639004A1 Fluorescein-labelled peptides |
| 03/29/2006 | EP1638919A1 Sphingolipids polyalkylamines conjugates |
| 03/29/2006 | EP1638611A1 Sphingolipids polyalkylamine conjugates for use in transfection |
| 03/29/2006 | EP1638610A1 Sphingoid polyalkylamine conjugates for vaccination |
| 03/29/2006 | EP1638596A2 Use of compositions comprising a soluble form of hla-g in the treatment of blood diseases |
| 03/29/2006 | EP1638595A1 Freeze-dried fsh / lh formulations |
| 03/29/2006 | EP1638594A1 Hip/pap polypeptide composition for use in liver regeneration and for the prevention of liver failure |
| 03/29/2006 | EP1638592A1 Synthetic peptide combinations and methods for the production thereof |
| 03/29/2006 | EP1638591A1 Class iii slrp agonists for the reduction of blood vessel formation |
| 03/29/2006 | EP1638590A2 Immune enhancing composition containing lactoferrin |
| 03/29/2006 | EP1638589A2 Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| 03/29/2006 | EP1638588A1 P-selectin targeting ligand and compositions thereof |
| 03/29/2006 | EP1638587A2 Contraceptive methods and compositions related to proteasomal interference |
| 03/29/2006 | EP1638581A2 Zwitterionic immunomodulators for the treatment of asthma and allergy |
| 03/29/2006 | EP1638575A2 Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| 03/29/2006 | EP1638567A1 Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases |
| 03/29/2006 | EP1638557A2 Glycogen synthase kinase-3 inhibitors |
| 03/29/2006 | EP1638541A2 Therapeutic agent for soft tissue sarcoma |
| 03/29/2006 | EP1638525A2 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 03/29/2006 | EP1638522A2 Solid drug formulation and device for storage and controlled delivery thereof |
| 03/29/2006 | EP1638512A2 Ligands that bind to the amyloid-beta; precursor peptide and related molecules and uses thereof |
| 03/29/2006 | EP1572919A4 Methods and compositions for use in homologous recombination |
| 03/29/2006 | EP1411971B1 Use of long pentraxin ptx3 for treating female infertility |
| 03/29/2006 | EP1409539B1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 03/29/2006 | EP1315747B1 Maurotoxin, pi1 and hstx1 derivatives |
| 03/29/2006 | EP1289552B1 Methods for treating hemostatic disorders by soluble p-selectin |
| 03/29/2006 | EP1283700B1 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 03/29/2006 | EP1251750B1 Improved pediatric formula and methods for providing nutrition and improving tolerance |
| 03/29/2006 | EP1230267B1 Membrane translocating peptide drug delivery system |
| 03/29/2006 | EP1226279B1 Modulation of neuroendocrine differentiation by protein 25.1 |